Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma
August 19, 2021 16:01 ET
|
Fate Therapeutics, Inc.
10 of 14 Patients in FT596 Single-Dose Escalation Cohorts 2 and 3 Achieved Objective Response; 7 Patients Achieved Complete Response, including 2 of 3 Patients Treated with FT596 in Combination with...
Fate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress
August 04, 2021 16:01 ET
|
Fate Therapeutics, Inc.
First Patient Treated for Relapsed / Refractory ALL in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-cell Therapy; Off-the-Shelf Product Candidate Derived from Clonal...
Fate Therapeutics Appoints Yuan Xu to its Board of Directors
August 04, 2021 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy
August 02, 2021 16:50 ET
|
Fate Therapeutics, Inc.
Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Phase 1 Clinical Study will Evaluate Three Dosing Regimens...
Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma
July 16, 2021 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2021 Financial Results
July 15, 2021 16:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics Appoints Mark Plavsic, DVM, PhD, RAC as Chief Technical Officer
June 15, 2021 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics Highlights Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma at 2021 ASCO Annual Meeting
June 04, 2021 07:00 ET
|
Fate Therapeutics, Inc.
8 of 11 Patients in Dose Escalation Cohorts 2 and 3 Achieved Objective Response 6 of 11 Patients Achieved Complete Response, including 2 Patients Previously Treated with Autologous CD19 CAR T-cell...
Fate Therapeutics to Present at Upcoming Investor Conferences
May 25, 2021 16:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for...
Fate Therapeutics Announces Encouraging Interim Phase 1 Data for iPSC-derived NK Cell Programs in Relapsed / Refractory Acute Myeloid Leukemia
May 13, 2021 16:01 ET
|
Fate Therapeutics, Inc.
4 of 9 Patients in FT516 Monotherapy Study Achieved Objective Response with Complete Leukemic Blast Clearance in the Bone Marrow 2 Patients in Second Dose Escalation Cohort of FT516 Monotherapy Study...